The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is targeting approximately USD 1.4 billion in export business opportunities for Indian pharmaceutical companies through iPHEX 2026, as the industry looks to expand its presence across global markets and build new international customer relationships.

The focus comes as India’s pharmaceutical exports recorded approximately 6.8 percent growth during the first quarter of FY27 over the corresponding period of FY26.

The 12th edition of iPHEX, to be organised by Pharmexcil with the support of the Department of Commerce, will be held from September 7-9 in Delhi. The 3-day exhibition and conference will bring together more than 800 exhibitors, over 600 overseas companies and neraly 30,000 business visitors, including manufacturers, exporters, buyers, distributors and procurement agencies.

Namit Joshi, Chairman, Pharmexcil, said, “The growth in pharmaceutical exports reflects the strength of Indian companies across products and markets. The opportunity now is to build on this base by expanding our engagement with international customers and identifying areas where Indian capabilities can meet demand across geographies. iPHEX 2026 is designed to facilitate that engagement and create opportunities for Indian companies to develop business relationships with overseas customers.”

With Indian pharmaceutical products reaching over 150 countries, iPHEX 2026 will focus on connecting Indian companies with buyers across markets and converting these interactions into export opportunities.

Structured buyer-seller meetings will enable Indian manufacturers and exporters to engage directly with international companies around product sourcing, supply partnerships, contract manufacturing and other forms of commercial engagement.

Nipun Jain, Chairman, iPHEX, said, “Global pharma business is built as much on trust as it is on capability. iPHEX brings both sides of that equation together with Indian companies ready to expand and international buyers looking for credible partners. Our intent is to move the engagement from converse to convert: from understanding a buyer’s requirement to finding the right Indian partner and taking that discussion towards business. And when these partnerships succeed, they become the strongest way to communicate the capability of Indian pharma to the next market.”

The Q1 performance also comes against a complex global trade environment, reinforcing the importance of expanding India’s pharmaceutical presence across markets and product categories. These trends will form an important context for iPHEX 2026, where Indian companies will showcase capabilities across formulations, Active Pharmaceutical Ingredients (APIs), biologicals, vaccines, biosimilars, contract manufacturing and medical devices.

With Indian pharmaceutical products reaching over 150 countries, market diversification will remain central to the discussions at iPHEX 2026. The event will provide Indian companies with an opportunity to explore demand across different geographies, understand evolving sourcing requirements and develop relationships with buyers beyond their existing international markets.

For Indian Micro, Small and Medium Enterprises (MSMEs) in particular, the international buyer participation is expected to provide direct access to markets and procurement networks that can otherwise take considerable time and resources to develop. Companies will be able to present their capabilities, understand market-specific requirements and explore the commercial viability of entering or expanding into different geographies.

Bhavin Mehta, Vice Chairman (VC), Pharmexcil, said, “India already has significant manufacturing capabilities across formulations, APIs, vaccines, biosimilars and other pharmaceutical segments. The next opportunity is to connect these capabilities with demand emerging across different international markets. Direct engagement with buyers gives companies, particularly MSMEs, a better understanding of what individual markets require and where they can compete effectively.”

The exhibition will showcase India’s capabilities across generics, APIs, finished formulations, biosimilars, vaccines, contract manufacturing and medical devices. Discussions will also cover sourcing partnerships, contract manufacturing and technology transfer, reflecting the widening scope of India’s pharmaceutical engagement with global markets.

Raja Bhanu, Director General (DG), Pharmexcil, said, “We are placing business engagement at the centre of iPHEX 2026. The buyer-seller meetings are being structured to enable focused discussions around sourcing requirements, products and potential partnerships. The objective is to create conversations that participating companies and buyers can take forward into commercial engagements beyond the exhibition.”

Beyond immediate business discussions, iPHEX 2026 will provide a platform for the industry to engage in the changing global pharmaceutical environment, including shifts in sourcing strategies, emerging market opportunities and the need for Indian exporters to build a broader geographical and product footprint.

Since its launch in 2013, iPHEX has provided Indian pharmaceutical and healthcare companies with a platform to engage directly with international markets. The 2026 edition builds on this role at a time when India’s pharmaceutical exports are showing growth across key categories, with the focus on converting international participation into business opportunities for Indian exporters.